Back to results
US 2002/0058804 A1Published application
Prodrug activation using catalytic antibodies
AssigneeThe Scripps Research Institute
InventorsCarlos F. Barbas III, Doron Shabat, Christoph Rader, Benjamin List, Richard A. Lerner
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound that includes an active therapeutic agent attached to a blocking moiety that is sensitive to the catalytic action of molecules having retro-aldol and retro-Michael catalytic activity, methods for making such compounds and methods of converting such compounds to active therapeutic agents using molecules having aldolase activity.
Claims25
A compound according to formula I, below
- 13
- where X is a heteroatom of a target molecule and Y is absent or a self-immolative linker and each R is independently hydrogen, C1-C6 alkyl, C1-C6 alkenyl, C5-C6 aryl or a heterocycle containing five or six ring atoms.
Dependencies are inferred from the claim text.